Copyright © 2009 Ariel Ernesto Cariaga-Martinez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. B. Gurel, T. Iwata, C. M. Koh, S. Yegnasubramanian, W. G. Nelson, and A. M. De Marzo, “Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets,” Advances in Anatomic Pathology, vol. 15, no. 6, pp. 319–331, 2008. View at Publisher · View at Google Scholar · View at PubMed
2. S. Wirén and P. Stattin, “Androgens and prostate cancer risk,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 22, no. 4, pp. 601–613, 2008. View at Publisher · View at Google Scholar · View at PubMed
3. D. Djakiew, “Dysregulated expression of growth factors and their receptors in the development of prostate cancer,” The Prostate, vol. 42, no. 2, pp. 150–160, 2000. View at Publisher · View at Google Scholar
4. B. J. Mayer, “Clues to the evolution of complex signaling machinery,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 9453–9454, 2008. View at Publisher · View at Google Scholar · View at PubMed
5. D. Qian and A. Weiss, “T cell antigen receptor signal transduction,” Current Opinion in Cell Biology, vol. 9, no. 2, pp. 205–212, 1997. View at Publisher · View at Google Scholar
6. J. I. Healy and C. C. Goodnow, “Positive versus negative signaling by lymphocyte antigen receptors,” Annual Review of Immunology, vol. 16, pp. 645–670, 1998. View at Publisher · View at Google Scholar · View at PubMed
7. K. A. Siminovitch, A. M. Lamhonwah, A. K. Somani, R. Cardiff, and G. B. Mills, “Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation,” Current Topics in Microbiology and Immunology, vol. 246, pp. 291–297, 1999.
8. L. A. J. O'Neill, “When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction,” Immunity, vol. 29, no. 1, pp. 12–20, 2008. View at Publisher · View at Google Scholar · View at PubMed
9. R. Roskoski, Jr., “Src kinase regulation by phosphorylation and dephosphorylation,” Biochemical and Biophysical Research Communications, vol. 331, no. 1, pp. 1–14, 2005. View at Publisher · View at Google Scholar · View at PubMed
10. G. Pani, K. D. Fischer, I. Mlinaric-Rascan, and K. A. Siminovitch, “Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase,” Journal of Experimental Medicine, vol. 184, no. 3, pp. 839–852, 1996. View at Publisher · View at Google Scholar
11. R. Roskoski, Jr., “Signaling by Kit protein-tyrosine kinase—the stem cell factor receptor,” Biochemical and Biophysical Research Communications, vol. 337, no. 1, pp. 1–13, 2005. View at Publisher · View at Google Scholar · View at PubMed
12. P. Brazeau, W. Vale, R. Burgus, et al., “Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone,” Science, vol. 179, no. 4068, pp. 77–79, 1973. View at Publisher · View at Google Scholar
13. Y. C. Patel, “Somatostatin and its receptor family,” Frontiers in Neuroendocrinology, vol. 20, no. 3, pp. 157–198, 1999. View at Publisher · View at Google Scholar · View at PubMed
14. Y. Taniyama, T. Suzuki, Y. Mikami, T. Moriya, S. Satomi, and H. Sasano, “Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study,” Endocrine Journal, vol. 52, no. 5, pp. 605–611, 2005. View at Publisher · View at Google Scholar
15. D. Ferone, P. M. van Hagen, C. Semino, et al., “Somatostatin receptor distribution and function in immune system,” Digestive and Liver Disease, vol. 36, pp. S68–S77, 2004. View at Publisher · View at Google Scholar
16. L. N. Møller, C. E. Stidsen, B. Hartmann, and J. J. Holst, “Somatostatin receptors,” Biochimica et Biophysica Acta, vol. 1616, no. 1, pp. 1–84, 2003. View at Publisher · View at Google Scholar
17. N. Benali, P. Cordelier, D. Calise, et al., “Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 9180–9185, 2000. View at Publisher · View at Google Scholar · View at PubMed
18. F. Tagliati, M. C. Zatelli, A. Bottoni, et al., “Role of complex cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro,” Endocrinology, vol. 147, no. 7, pp. 3530–3538, 2006. View at Publisher · View at Google Scholar · View at PubMed
19. F. Lopez, J.-P. Estève, L. Buscail, et al., “The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling,” The Journal of Biological Chemistry, vol. 272, no. 39, pp. 24448–24454, 1997. View at Publisher · View at Google Scholar
20. P. D. Zapata, R. M. Ropero, A. M. Valencia, et al., “Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 2, pp. 915–926, 2002. View at Publisher · View at Google Scholar
21. S. E. Alvarez, L. R. Seguin, R. S. Villarreal, C. Nahmias, and G. M. Ciuffo, “Involvement of c-Src tyrosine kinase in SHP-1 phosphatase activation by Ang II AT₂ receptors in rat fetal tissues,” Journal of Cellular Biochemistry, vol. 105, no. 3, pp. 703–711, 2008. View at Publisher · View at Google Scholar · View at PubMed
22. K. Bedecs, N. Elbaz, M. Sutren, et al., “Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase,” Biochemical Journal, vol. 325, no. 2, pp. 449–454, 1997.
23. N. Douziech, E. Calvo, Z. Coulombe, et al., “Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1,” Endocrinology, vol. 140, no. 2, pp. 765–777, 1999. View at Publisher · View at Google Scholar
24. C. Bousquet, N. Delesque, F. Lopez, et al., “sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1,” The Journal of Biological Chemistry, vol. 273, no. 12, pp. 7099–7106, 1998. View at Publisher · View at Google Scholar
25. A.-M. Valencia, J. L. Oliva, G. Bodega, et al., “Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate,” FEBS Letters, vol. 406, no. 1-2, pp. 42–48, 1997. View at Publisher · View at Google Scholar
26. C. Wu, M. Sun, L. Liu, and G. W. Zhou, “The function of the protein tyrosine phosphatase SHP-1 in cancer,” Gene, vol. 306, no. 1-2, pp. 1–12, 2003. View at Publisher · View at Google Scholar
27. G. Ferjoux, C. Bousquet, P. Cordelier, et al., “Signal transduction of somatostatin receptors negatively controlling cell proliferation,” Journal of Physiology, vol. 94, no. 3-4, pp. 205–210, 2000. View at Publisher · View at Google Scholar
28. P. D. Zapata, B. Colas, P. López-Ruiz, et al., “Phosphotyrosine phosphatase SHP-1, somatostatin and prostate cancer,” Actas Urológicas Españolas, vol. 28, no. 4, pp. 269–285, 2004.
29. Z. Z. Chong and K. Maiese, “The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury,” Histology and Histopathology, vol. 22, no. 11, pp. 1251–1267, 2007.
30. H. W. Tsui, K. Hasselblatt, A. Martin, S. C.-H. Mok, and F. W. L. Tsui, “Molecular mechanisms underlying SHP-1 gene expression,” European Journal of Biochemistry, vol. 269, no. 12, pp. 3057–3064, 2002. View at Publisher · View at Google Scholar
31. B. Bruecher-Encke, J. D. Griffin, B. G. Neel, and U. Lorenz, “Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation,” Leukemia, vol. 15, no. 9, pp. 1424–1432, 2001. View at Publisher · View at Google Scholar
32. V. Barresi, C. Alafaci, F. Salpietro, and G. Tuccari, “Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density?,” Oncology Reports, vol. 20, no. 3, pp. 485–492, 2008. View at Publisher · View at Google Scholar
33. U. Kumar, S. I. Grigorakis, H. L. Watt, et al., “Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology,” Breast Cancer Research and Treatment, vol. 92, no. 2, pp. 175–186, 2005. View at Publisher · View at Google Scholar · View at PubMed
34. T. Zhou, X. Xiao, B. Xu, H. Li, and Y. Zou, “Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways,” Acta Oncologica, vol. 48, no. 3, pp. 401–410, 2009. View at Publisher · View at Google Scholar · View at PubMed
35. T. Oka, T. Yoshino, K. Hayashi, et al., “Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray,” The American Journal of Pathology, vol. 159, no. 4, pp. 1495–1505, 2001.
36. G. Halmos, A. V. Schally, B. Sun, R. Davis, D. G. Bostwick, and A. Plonowski, “High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 7, pp. 2564–2571, 2000. View at Publisher · View at Google Scholar
37. A. A. Sinisi, A. Bellastella, D. Prezioso, et al., “Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 8, pp. 2566–2569, 1997. View at Publisher · View at Google Scholar
38. J. C. Reubi, B. Waser, J. C. Schaer, and R. Markwalder, “Somatostatin receptors in human prostate and prostate cancer,” The Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 9, pp. 2806–2814, 1995. View at Publisher · View at Google Scholar
39. S. A. Kaplan, “Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer,” The Journal of Urology, vol. 169, no. 4, p. 1621, 2003.
40. R. Tatoud, A. Degeorges, G. Prévost, et al., “Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog,” Molecular and Cellular Endocrinology, vol. 113, no. 2, pp. 195–204, 1995. View at Publisher · View at Google Scholar
41. M. Koppan, A. Nagy, A. V. Schally, J. M. Arencibia, A. Plonowski, and G. Halmos, “Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses,” Cancer Research, vol. 58, no. 18, pp. 4132–4137, 1998.
42. A. Plonowski, A. V. Schally, A. Nagy, B. Sun, and K. Szepeshazi, “Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238,” Cancer Research, vol. 59, no. 8, pp. 1947–1953, 1999.
43. D. Ferone, E. Resmini, M. Boschetti, et al., “Potential indications for somatostatin analogues: immune system and limphoproliferative disorders,” Journal of Endocrinological Investigation, vol. 28, pp. 111–117, 2005.
44. C. C. Delibrias, J. E. Floettmann, M. Rowe, and D. T. Fearon, “Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes,” Journal of Experimental Medicine, vol. 186, no. 9, pp. 1575–1583, 1997. View at Publisher · View at Google Scholar
45. C. Wu, Q. Guan, Y. Wang, Z. J. Zhao, and G. W. Zhou, “SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases,” Journal of Cellular Biochemistry, vol. 90, no. 5, pp. 1026–1037, 2003. View at Publisher · View at Google Scholar · View at PubMed
46. Q. Zhang, B. Lee, M. Korecka, et al., “Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I (+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia,” Leukemia Research, vol. 23, no. 4, pp. 373–384, 1999. View at Publisher · View at Google Scholar
47. Q. Zhang, P. N. Raghunath, E. Vonderheid, N. Ødum, and M. A. Wasik, “Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter,” The American Journal of Pathology, vol. 157, no. 4, pp. 1137–1146, 2000.
48. M. Thangaraju, K. Sharma, D. Liu, S.-H. Shen, and C. B. Srikant, “Interdependent regulation of intracellular acidification and SHP-1 in apoptosis,” Cancer Research, vol. 59, no. 7, pp. 1649–1654, 1999.
49. T.-S. Migone, N. A. Cacalano, N. Taylor, T. Yi, T. A. Waldmann, and J. A. Johnston, “Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3845–3850, 1998. View at Publisher · View at Google Scholar